P. Trainer

发表

Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.

M. Kołtowska-Häggström, B. Biller, C. Höybye, 2010, European journal of endocrinology.

of GH replacement in adults with controlled Cushing's disease

U. Feldt-Rasmussen, C. Høybye, O. Ragnarsson, 2010 .

The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.

A. Grossman, J. Newell-Price, P. Trainer, 1998, Endocrine reviews.

The radiological investigation of occult ectopic ACTH-dependent Cushing's syndrome.

R. Reznek, P. Armstrong, A. Marcus, 1993, Clinical radiology.

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials.

Camilo Jimenez, Michael O Thorner, W. Drake, 2008, European journal of endocrinology.

GHR Antagonist: Efficacy and Safety

P. Trainer, C. Higham, 2011 .

ACROSTUDY: the first 5 years.

P. Trainer, 2009, European journal of endocrinology.

Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

J. A. Scarlett, L. Phillips, M. Vance, 2000, The New England journal of medicine.

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.

M. Vance, W. Drake, D. Clemmons, 2005, The Journal of clinical endocrinology and metabolism.

Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.

W. Drake, J. Monson, P. Trainer, 2003, European journal of endocrinology.

Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary‐adrenal activity

J. Little, M. Korbonits, A. Grossman, 1997, Clinical endocrinology.

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

E. C. Stevens, J. Kopchick, P. Trainer, 2002, Endocrine reviews.

CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome.

R. Reznek, S. Sohaib, A. Grossman, 1999, AJR. American journal of roentgenology.

Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly

X. Badia, A. Forsythe, N. Biermasz, 2017, Journal of medical economics.

Exon splice enhancer mutation (GH-E32A) causes autosomal dominant growth hormone deficiency.

M. Dattani, I. Robinson, P. Clayton, 2007, The Journal of clinical endocrinology and metabolism.

Wide variation in surgical outcomes for acromegaly in the UK

M. Carson, J. Wass, P. Trainer, 2008, Clinical endocrinology.

The Place of Pegvisomant in the Management of Acromegaly

P. Trainer, C. Parkinson, 2003 .

Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.

K. Chihara, S. Melmed, A. Klibanski, 2003, The Journal of clinical endocrinology and metabolism.

Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN.

P. Chanson, A. Tabarin, M. Tóth, 2018, European journal of endocrinology.

Short and long‐term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

A. Grossman, T. Howlett, J. Verhelst, 1991, Clinical endocrinology.

Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.

G. Thompson, G. Besser, P. Trainer, 1992, The Quarterly journal of medicine.

A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome.

A. Grossman, G. Kaltsas, J. Newell-Price, 1999, The Journal of clinical endocrinology and metabolism.

Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement

B. Keevil, D. Cuthbertson, J. Valle, 2016, Annals of clinical biochemistry.

Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours

A. Lamarca, J. Valle, R. Hubner, 2016, Clinical endocrinology.

The use of mass spectrometry to improve the diagnosis and the management of the HPA axis

B. Keevil, P. Monaghan, P. Trainer, 2013, Reviews in Endocrine and Metabolic Disorders.

Corticosteroid‐binding globulin regulates cortisol pharmacokinetics

D. Ray, L. Aarons, D. Ray, 2011, Clinical endocrinology.

Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions.

D. Ray, B. Keevil, J. Newell-Price, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone

G. Brabant, B. Keevil, L. Owen, 2011, Annals of clinical biochemistry.

Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly

W. Drake, G. Besser, P. Trainer, 2001, Trends in Endocrinology & Metabolism.

Measurement of salivary cortisol with liquid chromatography‐tandem mass spectrometry in patients undergoing dynamic endocrine testing

G. Brabant, B. Keevil, L. Owen, 2010, Clinical endocrinology.

Salivary cortisone is a potential biomarker for serum free cortisol.

D. Ray, B. Keevil, P. Trainer, 2010, The Journal of clinical endocrinology and metabolism.

Acromegaly: Diagnosis and Management

P. Trainer, 2013 .

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide

N. Karavitaki, J. Wass, J. Byrne, 2008, Clinical endocrinology.

The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly.

P. Trainer, A. Claridge, S. Shakoor, 2006, European journal of endocrinology.

Recent developments in the therapy of acromegaly

A. Paisley, P. Trainer, 2006, Expert opinion on investigational drugs.

The place of pegvisomant in the acromegaly treatment algorithm.

W. Drake, A. Paisley, P. Trainer, 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Somatostatin analogue versus growth hormone antagonist treatment for acromegaly: who should get what?

A. Paisley, P. Trainer, S. Rowles, 2003 .

Medical treatment in acromegaly.

A. Paisley, P. Trainer, 2003, Current opinion in pharmacology.

Clinical Use of Pegvisomant for the Treatment of Acromegaly

W. Drake, P. Trainer, 2003, Treatments in endocrinology.

Medical Management of Cushing’s Syndrome

P. Trainer, C. Dang, 2010 .

IGF-I measurements in the monitoring of GH therapy

P. Trainer, C. Higham, A. Jostel, 2007, Pituitary.

Pharmacological management of Cushing's syndrome: an update.

P. Trainer, C. Dang, 2007, Arquivos brasileiros de endocrinologia e metabologia.

Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.

H. Randeva, W. Drake, A. Paisley, 2006, The Journal of clinical endocrinology and metabolism.

Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF‐I in adults with severe GH deficiency (GHD)

M. Bidlingmaier, C. Strasburger, S. Shalet, 2009, Clinical endocrinology.

Pituitary-independent effect of octreotide on IGF1 generation.

J. Frystyk, A. Flyvbjerg, P. Trainer, 2009, European journal of endocrinology.

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide

S. Samson, S. Melmed, M. Fleseriu, 2020, The Journal of clinical endocrinology and metabolism.

Determinants Of The Growth Hormone Nadir During Oral Glucose Tolerance Test In Adults - commentary.

P. Monaghan, P. Trainer, 2019, European journal of endocrinology.

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly

P. Chanson, W. Drake, D. Torpy, 2018, European journal of endocrinology.

Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.

B. Glaser, M. Korbonits, S. Melmed, 2015, The Journal of clinical endocrinology and metabolism.

High mortality within 90 days of diagnosis in patients with Cushing's syndrome - Results from the ERCUSYN registry.

P. Chanson, A. Tabarin, M. Tóth, 2019, European journal of endocrinology.

The effect of pegvisomant‐induced serum IGF‐I normalization on serum leptin levels in patients with acromegaly

G. Brabant, W. Drake, P. Clayton, 2003, Clinical endocrinology.

The cardiovascular phenotype of a mouse model of acromegaly.

A. Heagerty, J. Kopchick, L. Neyses, 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly

G. Besser, G. Wieringa, P. Trainer, 2002, Clinical endocrinology.

Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.

D. Russell-Jones, A. Umpleby, P. Trainer, 2009, The Journal of clinical endocrinology and metabolism.

Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution.

M. Korbonits, A. Grossman, P. Kopelman, 1996, Clinical endocrinology.

Differential stimulation of corticol and dehydropiandrosterone levels by food in obese and normal subjects: relation to body fat distribution

M. Korbonits, A. Grossman, P. Kopelman, 1996 .

A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.

W. Drake, K. Meeran, G. Besser, 2002, The Journal of clinical endocrinology and metabolism.

Pegvisomant in the treatment of acromegaly.

J. A. Scarlett, P. Trainer, C. Parkinson, 2003, Advanced drug delivery reviews.

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.

M. Korbonits, A. Grossman, G. Kaltsas, 1999, The Journal of clinical endocrinology and metabolism.

An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year

A. Grossman, J. Wass, G. Besser, 1994, Clinical endocrinology.

M. Korbonits, P. Dahia, A. Grossman, 2022 .

The effect of recombinant IGF‐I on anterior pituitary function in healthy volunteers

J. Holly, G. Besser, P. Trainer, 1994, Clinical endocrinology.

Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly

W. Drake, A. Paisley, P. Trainer, 2004, Expert opinion on biological therapy.

pharmacotherapy for the treatment of acromegaly

W. Drake, A. Paisley, P. Trainer, 2004 .

Current management practices for acromegaly: an international survey

P. Chanson, F. Casanueva, S. Melmed, 2011, Pituitary.

Effect of insulin‐like growth factor I on anterior pituitary function

P. Trainer, P. Trainer, 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly

Julian R. E. Davis, F. Roncaroli, P. Trainer, 2021, Neuroendocrinology.

Multidisciplinary management of acromegaly: A consensus

P. Chanson, A. Mamelak, F. Casanueva, 2020, Reviews in Endocrine and Metabolic Disorders.

Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists

J. Wass, T. Howlett, P. Trainer, 2013, Clinical endocrinology.

Treatment of acromegaly improves quality of life, measured by AcroQol

X. Badia, A. Paisley, L. Prieto, 2007, Clinical endocrinology.

Variation in GH and IGF‐I assays limits the applicability of international consensus criteria to local practice

G. Wieringa, P. Trainer, A. Ellis, 2007, Clinical endocrinology.

Pegvisomant interference in GH assays results in underestimation of GH levels.

K. Hayden, A. Paisley, G. Wieringa, 2007, European journal of endocrinology.

Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess

H. Reid, A. Heald, J. Kane, 2007, Annals of clinical biochemistry.

Pegvisomantinterferencein GHassaysresultsinunderestimation of GH levels

K. Hayden, A. Paisley, G. Wieringa, 2007 .

Consensus statement on the standardisation of GH assays.

J. Barth, P. Trainer, Cathie Sturgeon, 2006, European journal of endocrinology.

Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.

X. Badia, L. Prieto, S. Shalet, 2005, The Journal of clinical endocrinology and metabolism.

The Challenges of Reliance on Insulin-Like Growth Factor I in Monitoring Disease Activity in Patients with Acromegaly

A. Paisley, P. Trainer, 2005, Hormone Research in Paediatrics.

Pitfalls in the Diagnosis of Acromegaly

P. Trainer, A. Pokrajac-Simeunović, 2004, Hormone Research in Paediatrics.

Growth hormone assay standardization: a biased view?

J. Barth, G. Wieringa, P. Trainer, 2004, Clinical endocrinology.

High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization.

A. Flyvbjerg, P. Trainer, C. Parkinson, 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders.

S. Shalet, P. Jönsson, J. Monson, 2003, The Journal of clinical endocrinology and metabolism.

Acromegaly—Consensus, What Consensus?

P. Trainer, 2002 .

Gender and age influence the relationship between serum GH and IGF‐I in patients with acromegaly

S. O'dwyer, S. Shalet, P. Trainer, 2002, Clinical endocrinology.

A giant’s step forward

P. Trainer, P. J. Trainer, P. Trainer, 2002, Clinical endocrinology.

The relationship between serum GH and serum IGF-I in acromegaly is gender-specific.

W. Ryder, P. Trainer, C. Parkinson, 2001, The Journal of clinical endocrinology and metabolism.

Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.

J. Jenkins, A. Isidori, A. Grossman, 2001, The Journal of clinical endocrinology and metabolism.

State-of-the-art strategies for the diagnosis and management of acromegaly

S. Melmed, A. Klibanski, D. Clemmons, 2001 .

Therapeutic effects of neuroactive drugs on hypothalamo-pituitary in man.

A. Grossman, P. Trainer, 1990, Advances in experimental medicine and biology.

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.

A. Grossman, M. Savage, G. Besser, 1992, The Journal of endocrinology.

SUBCUTANEOUS GROWTH HORMONE‐RELEASING HORMONE AUGMENTS PULSATILE NOCTURNAL GH RELEASE IN GH‐INSUFFICIENT CHILDREN, BUT MAY ALSO RAISE BASAL GH SECRETION

A. Grossman, M. Savage, R. Ross, 1990, Clinical endocrinology.

Commentary: Harmonizing growth hormone measurements: learning lessons for the future.

G. Wieringa, P. Trainer, 2007, The Journal of clinical endocrinology and metabolism.

Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.

P. Trainer, C. Parkinson, 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Growth hormone receptor antagonists therapy for acromegaly.

P. Trainer, C. Parkinson, Peter J Trainer, 1999, Bailliere's best practice & research. Clinical endocrinology & metabolism.

P. Chanson, A. Tabarin, M. Tóth, 2018, Clinical endocrinology.

Growth Hormone Research Society perspective on biomarkers of GH action in children and adults

P. Chanson, S. Radovick, M. Dattani, 2018, Endocrine connections.

A prospective longitudinal study of Pasireotide in Nelson’s syndrome

S. Akker, A. Grossman, S. Walters, 2018, Pituitary.

Editorial: acromegaly--consensus, what consensus?

P. Trainer, 2002, The Journal of clinical endocrinology and metabolism.

Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond.

B. Keevil, P. Stewart, P. Monaghan, 2014, The Journal of clinical endocrinology and metabolism.

New causes of hypophysitis.

K. Yuen, V. Popović, P. Trainer, 2019, Best practice & research. Clinical endocrinology & metabolism.

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy

J. Larkin, P. Carroll, P. Lorigan, 2018, Endocrine connections.

Hyponatraemia secondary to nivolumab-induced primary adrenal failure

P. Lorigan, P. Trainer, P. Hulse, 2016, Endocrinology, diabetes & metabolism case reports.

Quantitative growth hormone secretion and final adult height

G. Delitala, G. Fanciulli, G. Besser, 1999, Clinical endocrinology.

Emergency management of immune‐related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes

P. Lorigan, T. Cooksley, P. Trainer, 2018, Cancer.

The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human.

M. Korbonits, A. Grossman, P. Stewart, 1998, The Journal of clinical endocrinology and metabolism.

The effect of an opiate antagonist on the hormonal changes induced by hexarelin

M. Korbonits, G. Besser, P. Trainer, 1995, Clinical endocrinology.

A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis.

A. Grossman, D. Coy, J. Newell-Price, 1995, The Journal of clinical endocrinology and metabolism.

Acute management of the endocrine complications of checkpoint inhibitor therapy

J. Larkin, P. Carroll, P. Lorigan, 2018 .

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

W. Drake, A. Grossman, G. Kaltsas, 1998, The Journal of clinical endocrinology and metabolism.

Clinical experience of the efficacy and safety of low dose tolvaptan therapy in a UK tertiary oncology setting.

G. Brabant, F. Blackhall, A. Kyriacou, 2021, The Journal of clinical endocrinology and metabolism.

The diagnosis and differential diagnosis of Cushing's syndrome

A. Grossman, P. Trainer, 1991, Hormone research.

A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome

A. Grossman, J. Newell-Price, J. Wass, 1995, Clinical endocrinology.

Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN.

P. Chanson, A. Tabarin, M. Tóth, 2017, European journal of endocrinology.

Mass spectrometry for the endocrine clinic – much to digest

B. Keevil, P. Monaghan, P. Trainer, 2013, Clinical endocrinology.

Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man.

A. Grossman, G. Delitala, G. Fanciulli, 1994, The Journal of endocrinology.

Metabolic effects of GH antagonism in patients with acromegaly.

P. Trainer, 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency.

M. Dattani, P. Hindmarsh, P. Clayton, 2009, The Journal of clinical endocrinology and metabolism.

Endocrine investigation: Cushing's syndrome

R. Ross, P. Trainer, R. Ross, 1998, Clinical endocrinology.

Novel corticosteroid-binding globulin variant that lacks steroid binding activity.

D. Ray, W. Newman, S. Lightman, 2010, The Journal of clinical endocrinology and metabolism.

How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?

M. Korbonits, A. Isidori, A. Grossman, 2000, Clinical endocrinology.

Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successfuI treatment

D. Lowe, A. Grossman, M. Savage, 1993, Clinical endocrinology.

Complications of inferior petrosel sinus sampling.

A. Grossman, G. Kaltsas, J. Newell-Price, 2000, The Journal of clinical endocrinology and metabolism.

Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.

A. Grossman, J. Newell-Price, L. Perry, 1998, The Journal of clinical endocrinology and metabolism.

The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome.

A. Grossman, P. Jenkins, J. Wass, 1995, The Journal of clinical endocrinology and metabolism.

Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.

A. Flyvbjerg, M. Kassem, L. Heickendorff, 2003, The Journal of clinical endocrinology and metabolism.

Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.

P. Burman, P. Trainer, M. Messig, 2007, The Journal of clinical endocrinology and metabolism.

Current management and outcome of pregnancies in women with adrenal insufficiency: experience from a multi-center survey.

K. Badenhoop, R. Murray, F. Beuschlein, 2020, The Journal of clinical endocrinology and metabolism.

GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH.

S. Thiel, R. Dall, J. Jørgensen, 2001, The Journal of clinical endocrinology and metabolism.

Benzodiazepines attenuate the pituitary‐adrenal responses to corticotrophin‐releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome

M. Korbonits, A. Grossman, A. Grossman, 1995, Clinical endocrinology.

Cushing's syndrome. Therapy directed at the adrenal glands.

P. Trainer, M. Besser, 1994, Endocrinology and metabolism clinics of North America.

A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.

R. Murray, W. Drake, N. Martin, 2016, The Journal of clinical endocrinology and metabolism.

Treatment with GHRH(1‐29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity

M. Savage, G. Besser, J. Kirk, 1994, Clinical endocrinology.

Pyridostigmine fails to increase either spontaneous or GHRH‐stimulated GH secretion during day or night in growth hormone‐insufficient children

M. Savage, R. Ross, G. Besser, 1991, Clinical endocrinology.

A subnormal peak cortisol response to stimulation testing does not predict a subnormal cortisol production rate.

A. Paisley, P. Trainer, D. Brandon, 2007, The Journal of clinical endocrinology and metabolism.

Malignant prolactinoma with extracranial metastases: a report of three cases

John D. Walker, P. Sönksen, D. Lowe, 1993, Clinical endocrinology.

HOW TO OPTIMISE PEGVISOMANT TREATMENT OF ACROMEGALY SAFELY

S. Shalet, J. Monson, P. Trainer, 2002 .

Giant leaps forward.

P. Trainer, 2009, Clinical medicine.

Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.

W. Drake, N. Taylor, L. Perry, 2001, The Journal of clinical endocrinology and metabolism.

Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy

T. Lister, R. Reznek, S. Sohaib, 1999, British Journal of Cancer.

New options for the medical treatment of Cushing's syndrome

P. Trainer, 2013, Indian journal of endocrinology and metabolism.

Cushing's syndrome difficulties in diagnosis

P. Trainer, M. Besser, 1990, Trends in Endocrinology & Metabolism.

Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization.

A. Kyriacou, J. Lawrance, P. Trainer, 2015, Hormones.

Lessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY

M. Buchfelder, A. Luger, U. Feldt-Rasmussen, 2011, Hormone Research in Paediatrics.

Hexarelin as a test of pituitary reserve in patients with pituitary disease

M. Korbonits, A. Grossman, G. Kaltsas, 1999, Clinical endocrinology.

Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.

Julian R. E. Davis, W. Drake, A. Grossman, 2015, The Journal of clinical endocrinology and metabolism.

ACTH Antagonists

J. Newell-Price, A. Clark, Li Chan, 2016, Front. Endocrinol..

Nitric oxide modulates the release of vasopressin from rat hypothalamic explants.

A. Grossman, M. Forsling, P. Trainer, 1993, Endocrinology.

The hormonal assessment of the infertile male.

P. Trainer, N. Islam, 1998, British journal of urology.

University of Birmingham Patient reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly

I. Kreitschmann-Andermahr, M. Korbonits, S. Störmann, 2016 .

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

J. A. Scarlett, R. K. Hutson, M. Vance, 2001, The Lancet.

The place of pegvisomant in the management of acromegaly

P. Trainer, C. Parkinson, 2001, Expert opinion on investigational drugs.

Nitric oxide modulates the release of corticotropin-releasing hormone from the rat hypothalamus in vitro

A. Grossman, Alfredo Costa, P. Trainer, 1993, Brain Research.

Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

P. Chanson, A. Mamelak, R. Fahlbusch, 2017, Pituitary.

Changes in arterial stiffness but not carotid intimal thickness in acromegaly.

M. Rezai, M. Banerjee, A. Paisley, 2011, The Journal of clinical endocrinology and metabolism.

Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly.

K. Cruickshank, I. Gemmell, A. Heagerty, 2009, The Journal of clinical endocrinology and metabolism.

Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors

Julian R. E. Davis, H. Randeva, R. Eeles, 2020, The Journal of clinical endocrinology and metabolism.

Clinical, radiological and pathological features of patients with Rathke's cleft cysts: tumors that may recur.

D. Lowe, J. J. Mukherjee, A. Grossman, 1997, The Journal of clinical endocrinology and metabolism.

Acute polyneuropathy with chronic lymphocytic leukaemia and paraproteinaemia: response to chlorambucil and prednisolone

W. Drake, J. Dick, J. Monson, 1998, Journal of neurology, neurosurgery, and psychiatry.

Founder Effect in Recurring AIP Mutation Causing Familial Isolated Pituitary Adenoma Syndrome

P. Chanson, Mark George Thomas, S. Ellard, 2014 .

Adjuvant immunotherapy: the sting in the tail.

A. Eggermont, P. Lorigan, P. Trainer, 2020, European journal of cancer.

The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics.

Miklós Tóth, P. Chanson, A. Tabarin, 2011, European journal of endocrinology.

Endoscopic Transsphenoidal Pituitary Surgery: Evidence of an Operative Learning Curve

Julian R. E. Davis, P. Trainer, K. Gnanalingham, 2010, Neurosurgery.

Transsphenoidal resection in Cushing's disease: definition of success

G. Chrousos, B. Fauser, T. Friedman, 1993, Clinical endocrinology.

The Adrenals in Oncology

G. Boland, J. Coen, P. Trainer, 2009 .

Evaluation of pituitary function.

Kelly Cheer, P. Trainer, 2014, Handbook of clinical neurology.

Novel corticosteroid-binding globulin variant that lacks steroid binding activity.

D. Ray, W. Newman, S. Lightman, 2010, The Journal of clinical endocrinology and metabolism.

Regulation of cortisol bioavailability—effects on hormone measurement and action

D. Ray, P. Trainer, I. Perogamvros, 2012, Nature Reviews Endocrinology.

Recalibration of thinking about adrenocortical function assessment: how the ‘random’ cortisol relates to the short synacthen test results

A. Fryer, A. Heald, G. Yadegarfar, 2019, Cardiovascular endocrinology & metabolism.

What is the value of the 60‐minute cortisol measurement in the short synacthen test (SST)? Evidence for the defence

A. Fryer, A. Heald, G. Yadegarfar, 2021, International journal of clinical practice.

The Bart's endocrine protocols

G. Besser, P. Trainer, 1995 .

Disorders of water balance.

C. Thompson, P. Trainer, K. Moore, 2003, Clinical medicine.

A consensus on criteria for cure of acromegaly.

P. Chanson, F. Casanueva, S. Melmed, 2010, The Journal of clinical endocrinology and metabolism.

Response to ‘Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone’ by Halsall et al.

G. Brabant, B. Keevil, L. Owen, 2012 .

Acromegaly Surgery in Manchester Revisited: The Impact of Reducing Surgeon Numbers and the 2010 Consensus Guidelines for Disease Remission

Julian R. E. Davis, P. Trainer, K. Gnanalingham, 2012 .

Successful use of weekly pegvisomant administration in patients with acromegaly.

W. Drake, M. Bidlingmaier, J. D. Thomas, 2008, European journal of endocrinology.

Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

P. Chanson, S. Radovick, A. Mamelak, 2021, Journal of the Endocrine Society.

Next generation medical therapy for Cushing's syndrome--can we measure a benefit?

P. Trainer, 2014, The Journal of clinical endocrinology and metabolism.

Current Status and Future Opportunities for Controlling Acromegaly

M. Vance, S. Melmed, A. Klibanski, 2004, Pituitary.

Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome

A. Grossman, M. Savage, A. Grossman, 1995, Clinical endocrinology.

Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome.

R. Reznek, S. Sohaib, A. Grossman, 1999, The Journal of clinical endocrinology and metabolism.

Cushing's disease

P. Trainer, M. Besser, 2000, The Lancet.

Proopiomelanocortin interference in the measurement of adrenocorticotrophic hormone: a United Kingdom National External Quality Assessment Service study

C. Sturgeon, A. Kyriacou, A. White, 2016, Clinical endocrinology.

Corticosteroids and Pregnancy

P. Trainer, 2002, Seminars in reproductive medicine.

Growth hormone excess and the development of growth hormone receptor antagonists

P. Trainer, C. Higham, Peter J Trainer, 2008, Experimental physiology.

Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.

W. Drake, M. Bidlingmaier, N. Martin, 2012, The Journal of clinical endocrinology and metabolism.

Long‐term experience of pegvisomant therapy as a treatment for acromegaly

W. Drake, T. Chung, J. Lawrance, 2009, Clinical endocrinology.

Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.

W. Drake, S. Akker, G. Besser, 2001, European journal of endocrinology.

ACROSTUDY: An Overview

P. Trainer, 2007, Hormone Research in Paediatrics.

Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.

W. Drake, G. Besser, R. Loureiro, 2002, European journal of endocrinology.

Studies on the regulation of growth hormone secretion in man

Peter James Trainer, P. Trainer, 1997 .

Acromegaly surgery in Manchester revisited – The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission

Julian R. E. Davis, P. Trainer, K. Gnanalingham, 2012, Clinical endocrinology.

Title: Successful use of weekly pegvisomant administration in patients with acromegaly Short title: Weekly pegvisomant for acromegaly

M. Bidlingmaier, P. Trainer, C. Higham, 2009 .

Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems

A. Paisley, P. Trainer, M. Roberts, 2007, Clinical endocrinology.

Early diagnosis of acromegaly: computers vs clinicians

Volker Blanz, Ralph E. Miller, Angela Paisley, 2011, Clinical endocrinology.

The pituitary gland and age-dependent regulation of body composition.

B. Wolffenbuttel, A. V. van Beek, M. Kołtowska-Häggström, 2010, The Journal of clinical endocrinology and metabolism.

Quality assurance in the analysis of growth hormone and insulin-like growth factor I in disorders of the somatotropic axis

H. Wallaschofski, M. Bidlingmaier, M. Ranke, 2016 .

Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels.

B. Keevil, E. Urgell, S. Webb, 2017, European journal of endocrinology.

The effects on anterior pituitary hormone secretion of salmon calcitonin in healthy volunteers

G. Besser, J. Kirk, P. Trainer, 1991, Clinical endocrinology.

Effectiveness of metyrapone in 195 patients with Cushing's syndrome

Julian R. E. Davis, W. Drake, A. Grossman, 2014 .

Advances in Our Understanding of Acromegaly - Is There an Optimal Management Regimen?

P. Trainer, C. Higham, 2009 .

Is withdrawal of somatostatin analogue therapy in patients with acromegaly associated with an increased risk of acute biliary problems?

A. Paisley, P. Trainer, 2008 .

Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall

S. Ezzat, S. Imran, P. Trainer, 2010, International journal of endocrinology.

In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism

D. Balding, P. Chanson, Mark George Thomas, 2017, European journal of endocrinology.

L-arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide.

M. Korbonits, A. Grossman, G. Delitala, 1996, European journal of endocrinology.

Lessons from 6 years of GH receptor antagonist therapy for acromegaly.

P. Trainer, 2003, Journal of endocrinological investigation.

Urinary Free Cortisol in the Assessment of Hydrocortisone Replacement Therapy

K. Mchardy, R. Harvey, P. Trainer, 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly

S. Ezzat, C. Strasburger, G. Layton, 2009, Clinical endocrinology.

Detecting Acromegaly: Screening for Disease with a Morphable Model

Qifeng Lu, Erik G. Learned-Miller, Volker Blanz, 2006, MICCAI.